Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "xcell"

Looking for quality documents?
external link icon
Repligen Appoints Jonathan I. Lieber as CFO
- Former CFO of Xcellerex, Inc. Joins Repligen Executive Management Team - Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jonathan I. Lieber to the position of Chief Financial Officer and Treasurer, effective immediately. Mr. Lieber most recently held the position of CFO and Treasurer at Xcellerex, Inc., a supplier of bioprocessing products and disposable biomanufacturing technologies, which was acquired in May 2012 by GE Healthcare. He will be responsible for leading Repligen’s financial activities, including long-term financial strategy and risk management. Repligen’s current CFO William J. Kelly has been named Chief Accounting Officer, overseeing the Company’s accounting and management reporting functions, as well as its internal controls. “We are pleased to welcome Jonathan Lieber to the CFO role,” said Walter C. Herlihy, Ph.D., President and Chief Executive Officer at Repligen. “Over the past nine months, Repligen has become a profitable, significantly
news icon
More cells, faster.
Simplify and intensify upstream bioprocessing. The XCell® ATF System, in single-use or stainless steel format, delivers high cell retention.
external link icon
Repligen to Participate in 14th Annual Craig-Hallum Institutional Investor Conference
WALTHAM, Mass., May 24, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that management will participate in the 14 th Annual Craig-Hallum Institutional Investor Conference, to be held in Minneapolis on Wednesday, May 31, 2017.
About Repligen Corporation Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to improve the biological drug manufacturing process. Our portfolio includes Protein products (Protein A affinity ligands, cell culture growth factors), Chromatography products (OPUS® pre-packed columns, chromatography resins, ELISA kits) and Filtration products (XCell™ ATF Systems, TangenX™ Sius™ TFF cassettes). Our bioprocessing products are sold to major life sciences companies, biopharmaceutical development companies and contract manufacturing organizations worldwide. We
external link icon
Repligen Opens Training & Innovation Center to Elevate Customer Experience
WALTHAM, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its Repligen Training & Innovation Center (“RTIC”) at its Waltham headquarters. The opening celebration, held on the evening of September 23, attracted a group of over 150 biopharma and CDMO customers. The RTIC buildout, which features product exhibits, purpose-built demonstration areas and technical training space, was designed to provide customers with pre- and post-sales support, and provide a hands-on experience with Repligen’s innovative bioprocessing solutions. The RTIC enables the functional display of all Repligen bioprocessing technologies; a complete collection from across the company’s global manufacturing sites. Upstream intensification technologies include XCell ® ATF and KrosFlo ® TFDF ® devices and controllers. Downstream products include OPUS ® pre-packed chromatography
external link icon
Repligen to Present at Jefferies 2019 Healthcare Conference
WALTHAM, Mass., June 04, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that Jon K. Snodgres, Chief Financial Officer, will present at the Jefferies 2019 Global Healthcare Conference on Thursday, June 6 at 8:30 a.m. EDT.
A live audio webcast of the presentation will be accessible through the Investor Events section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes filtration products (including XCell™ ATF, TangenX™ SIUS™ TFF and Spectrum KrosFlo™ TFF filters and systems), chromatography products (OPUS® pre-packed columns, chromatography resins,
external link icon
Repligen to Present at Baird’s 2017 Global Healthcare Conference
WALTHAM, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that management will present at Baird’s 2017 Healthcare Conference in New York on Wednesday, September 6, at 9:05 a.m. EDT. A live webcast of the presentation will be accessible through the Investor Events section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes protein products (Protein A affinity ligands, cell culture growth factors), chromatography products (OPUS® pre-packed columns, chromatography resins, ELISA kits) and filtration products (including XCell™ ATF systems,
external link icon
Repligen Corporation and Spectrum, Inc. to Join Forces
- Adds to Repligen a leader in bioprocess filtration with expertise in hollow fiber technology
- Strengthens flagship XCell™ ATF product line with an extensive filtration consumables portfolio
- Diversifies markets beyond monoclonal antibody manufacturing into vaccine, recombinant protein and gene therapy production
- Expands global commercial organization and adds direct sales in the US, Europe and Asia
- Deal expected to be accretive to Repligen earnings per share in fiscal 2018 WALTHAM, Mass., June 23, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive merger agreement with privately-held Spectrum, Inc. (“Spectrum”) for approximately $359 million, comprised of $120 million in cash plus 6,154,000 shares of Repligen stock. Spectrum recorded revenue of $40.2 million in 2016, with greater than 90% coming from its filtration
external link icon
UPDATE -- Repligen Acquires TangenX Technology Corporation
WALTHAM, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has acquired TangenX Technology Corporation (“TangenX”) of Shrewsbury, MA, maker of the innovative single-use Sius™ line of tangential flow filtration (“TFF”) cassettes and hardware used in downstream biopharmaceutical manufacturing processes.  Sius TFF is used in the filtration of biological drugs, complementing Repligen’s OPUS® line of Pre-Packed Chromatography Columns used in downstream purification. Single-use Sius TFF cassettes are designed to deliver superior performance to traditional (reusable) TFF cassettes in a cost-competitive format that provides user-ready convenience and flexibility. The Sius portfolio also strengthens the Company’s existing capability in filtration, where its XCell™ ATF products (both stainless steel and single-use) are used for perfusion and cell culture intensification
external link icon
Repligen Reports Second Quarter 2016 Financial Results
WALTHAM, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the second quarter ended June 30, 2016. Detailed in this press release are the Company's performance highlights for the period, followed by updated financial guidance for the year 2016 and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We continue to be encouraged by the strength in demand for our bioprocessing products and the positive trends in our industry. We achieved record revenue of $29.2 million in the second quarter of 2016, an increase of 36% from the same period in 2015, driven by strong demand for OPUS® purification columns, XCell™ ATF systems and growth factors. It was also an important quarter in terms of executing on our long-term growth strategy. In April, we acquired Atoll GmBH (“Atoll”), and in May we
external link icon
Repligen Reports Third Quarter 2024 Financial Results
Third quarter reported revenue of $155 million, an increase of 10% year-over-year CDMO revenue and orders both up ~20% year-over-year Overall order intake outpaced sales by 4% Full year revenue guidance narrowed to range of $630-$639 million WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter (Q3) of 2024, covering the three- and nine- month periods ended September 30, 2024. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2024 and access information for today’s webcast and conference call. Olivier Loeillot, President and Chief Executive Officer of Repligen said, “I’m pleased to report strong third quarter results, made possible by the excellent execution by our team and improving market conditions. We are encouraged to see strengthening CDMO and equipment sales in